Neuropharmacological profile of novel and selective 5-HT6 receptor agonists: WAY-181187 and WAY-208466 - Wikidata - wikimedia - TriplyDB

Neuropharmacological profile of novel and selective 5-HT6 receptor agonists: WAY-181187 and WAY-208466

Neuropharmacological profile of novel and selective 5-HT6 receptor agonists: WAY-181187 and WAY-208466

http://www.wikidata.org/entity/Q28236198

about

5-HT(6) receptor recruitment of mTOR as a mechanism for perturbed cognition in schizophrenia Antidepressant and anxiolytic effects of selective 5-HT6 receptor agonists in rats Effects of serotonin in the hippocampus: how SSRIs and multimodal antidepressants might regulate pyramidal cell function 5-HT6 receptors and Alzheimer's disease The serotonin 5-HT6 receptor: a viable drug target for treating cognitive deficits in Alzheimer's disease Study of a mechanism responsible for potential antidepressant activity of EMD 386088, a 5-HT6 partial agonist in rats 5-HT6 receptor antagonists as novel cognitive enhancing agents for Alzheimer's disease Serotonin receptor expression in human prefrontal cortex: balancing excitation and inhibition across postnatal development The Concise Guide to PHARMACOLOGY 2013/14: G protein-coupled receptors Altered γ-aminobutyric acid neurotransmission in major depressive disorder: a critical review of the supporting evidence and the influence of serotonergic antidepressants Behavioral Biomarkers of Schizophrenia in High Drinker Rats: A Potential Endophenotype of Compulsive Neuropsychiatric Disorders.Effect of acute and chronic electroconvulsive shock on 5-hydroxytrypamine 6 receptor immunoreactivity in rat hippocampus.The BTBR mouse model of autism spectrum disorders has learning and attentional impairments and alterations in acetylcholine and kynurenic acid in prefrontal cortex.Alzheimer's disease and age-related memory decline (preclinical)Increased expression of 5-HT₆ receptors in dorsolateral striatum decreases habitual lever pressing, but does not affect learning acquisition of simple operant tasks in rats.Deconstructing 5-HT6 receptor effects on striatal circuit function.Neurotransmitter receptors and cognitive dysfunction in Alzheimer's disease and Parkinson's disease.The role of serotonin receptor subtypes in treating depression: a review of animal studies 5-HT6 receptor agonism facilitates emotional learning.5-HT(6) receptor agonists and antagonists enhance learning and memory in a conditioned emotion response paradigm by modulation of cholinergic and glutamatergic mechanisms.Serotonin 6 receptor controls Alzheimer's disease and depression Increased expression of the 5-HT6 receptor by viral mediated gene transfer into posterior but not anterior dorsomedial striatum interferes with acquisition of a discrete action-outcome task.Activation of 5-HT6 receptors modulates sleep-wake activity and hippocampal theta oscillation The role of serotonin in the NMDA receptor antagonist models of psychosis and cognitive impairment.Role of serotonin in Alzheimer's disease: a new therapeutic target?Schedule-induced polydipsia as a model of compulsive behavior: neuropharmacological and neuroendocrine bases.The serotonin-6 receptor as a novel therapeutic target.5HT(6) receptor antagonists: a patent update. Part 1. Sulfonyl derivatives.Leading compounds for the validation of animal models of psychopathology.Pharmacological approaches for Alzheimer's disease: neurotransmitter as drug targets.Antidepressant-like activity of EMD 386088, a 5-HT6 receptor partial agonist, following systemic acute and chronic administration to rats.Investigational drugs targeting 5-HT6 receptors for the treatment of Alzheimer's disease.Emerging chemical therapies targeting 5-hydroxytryptamine in the treatment of Alzheimer's disease.Effects of ST1936, a selective serotonin-6 agonist, on electrical activity of putative mesencephalic dopaminergic neurons in the rat brain.The 5-HT6 receptor agonist EMD 386088 produces antidepressant and anxiolytic effects in rats after intrahippocampal administration.The 5-hydroxytryptamine (serotonin) receptor 6 agonist EMD 386088 ameliorates ketamine-induced deficits in attentional set shifting and novel object recognition, but not in the prepulse inhibition in rats.The frontal cortex as a network hub controlling mood and cognition: Probing its neurochemical substrates for improved therapy of psychiatric and neurological disorders.Dorsomedial prefrontal cortex 5-HT6 receptors regulate anxiety-like behavior.Comparative effects of sertraline, haloperidol or olanzapine treatments on ketamine-induced changes in mouse behaviours.Activation of serotonin 5-HT2A receptors inhibits high compulsive drinking on schedule-induced polydipsia.

P2860

Q24299992-1555F3FA-DEBE-4BD4-964A-4E6A9F606C8F Q24602751-341F4798-F672-4A65-AA3C-9A547D677E45 Q26783101-B0001A82-92D7-49A7-AFBA-AFB34374090C Q27006820-8CBC391F-A54D-45E3-AF6C-2C35D3737AD0 Q28251394-3739517A-D2FB-405C-91DA-D6724B618932 Q28275114-005C9E3B-9CC6-4EF4-A385-93CC0B516B28 Q28287100-C60FE579-3EDB-4147-8902-5F085DCC7130 Q28741999-5A72856C-4425-440D-A7F7-838330629C14 Q30486707-E64C3F02-422C-4B13-8AD6-D04CFBAA04A3 Q30887852-9E70512A-9F4B-4B04-B7AF-79DB857F7F66 Q33802768-4EF029F7-9FC8-483D-8183-3E6FC1715532 Q34241575-D194A469-2D15-4821-A8B7-F0A3F61B9819 Q34701031-EC6EB43B-4493-4F08-B903-6DC4AB2CBECB Q35041190-152C2682-D630-4F28-BFA2-EE6AC6DD7A92 Q35112806-F2005F57-7310-4FE1-8595-3130C54C226B Q35688656-EA143B85-958B-495F-8ECE-F62EE27BC8AB Q36020776-896AC08F-5585-4348-9D2B-8F015D0DCB62 Q36031101-A3FD8623-6887-4FF6-A041-27C3A45A8D49 Q36097366-2154CB1A-2050-4601-84F8-650F6B853463 Q36346938-33E1D203-EF04-42DB-B382-E3A08E1570B8 Q36413592-39A0D859-C2AB-4264-97A3-430648715F4E Q36490844-108C417B-C950-44D2-9638-F32EAC18A132 Q36540905-EDD8B939-98B5-4006-A1D8-914697099609 Q37826638-6F47865D-1E06-45C9-9E71-DF4892AED8A5 Q37922766-61D3DD84-5DF8-4115-A80A-9FDCE75996D3 Q37960352-1A47B821-4D97-43BF-9630-CF7610EDAE10 Q37987116-9469F094-3C7B-4895-B09C-F8DFFBF4ACC9 Q38027891-A7D4A8B2-978B-4B77-9D38-CF33BA455695 Q38128733-C508186E-8EA4-4203-B01D-0AA270786F5D Q38286222-A71E8C83-BF56-42E4-AC1B-A194358CFFB0 Q38298300-EDA84A6E-5E95-42D9-B35E-ED99A684B12A Q38627971-DE9E4FDD-06FB-4E0B-A373-2430F562A255 Q39158422-61433A54-ABD8-461C-A493-620871A61309 Q41307502-ECFEAE65-1145-4A3F-B2B4-EDEDDF005C11 Q42597841-01728C55-C91B-430D-BB14-9906020D2F4B Q44655683-046D3159-974C-4DE8-97EF-34E1EFDF7C83 Q47382890-8F4BC523-EBBC-403D-A8CF-8913CFC457DC Q47587262-CEE8A21B-44D3-45F9-84F2-0B2539771DCB Q47869087-FE7374A5-8A94-44F0-9E5E-39ECC186EA47 Q48586285-ECB0FA39-8312-4663-A676-0951F87A96B9

P2860

Neuropharmacological profile of novel and selective 5-HT6 receptor agonists: WAY-181187 and WAY-208466

http://www.wikidata.org/entity/Q28236198

description

2008 nî lūn-bûn

@nan

2008 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

name

Neuropharmacological profile o ...... sts: WAY-181187 and WAY-208466

@ast

Neuropharmacological profile o ...... sts: WAY-181187 and WAY-208466

@en

Neuropharmacological profile o ...... sts: WAY-181187 and WAY-208466

@nl

type

label

Neuropharmacological profile o ...... sts: WAY-181187 and WAY-208466

@ast

Neuropharmacological profile o ...... sts: WAY-181187 and WAY-208466

@en

Neuropharmacological profile o ...... sts: WAY-181187 and WAY-208466

@nl

prefLabel

Neuropharmacological profile o ...... sts: WAY-181187 and WAY-208466

@ast

Neuropharmacological profile o ...... sts: WAY-181187 and WAY-208466

@en

Neuropharmacological profile o ...... sts: WAY-181187 and WAY-208466

@nl

P1433

Q28236198-1D220220-0333-4D60-A60E-D0AB2514F624

P1476

Q28236198-11C457C5-C58D-49B2-B627-BF80B93A85B0

P2093

Q28236198-0964B442-9FC4-48A4-80D0-A8074805660E

Q28236198-314A3552-3E38-49D3-9083-A17C1630C7D5

Q28236198-4EE7AFBC-8149-4A8B-91D5-64829FCF7883

Q28236198-5624A5B0-1FC2-493F-A683-AD3D3D806880

Q28236198-6C11E534-00C0-4797-9125-1DCB6536A9EC

Q28236198-768392EE-E252-4E5C-BA0B-6147F69891C8

Q28236198-76CFFFB5-C049-40AB-A893-4AFBD5883573

Q28236198-80696FCF-8F7F-43BC-A7A5-89A04E100F23

Q28236198-B3C7B227-AF9A-4D6A-A226-4C27424699BC

Q28236198-D5EFEE4E-86A9-4363-845E-F15A87D9AF8D

P2860

Q28236198-06CB4724-0625-4D34-9B10-0394DDAD27DF

Q28236198-0700E94C-2B97-48F0-A0FF-F72C66AF7755

Q28236198-08BD10F0-0938-4C5E-A776-3FA72A578035

Q28236198-0A26DFE7-F21B-4E7F-913E-A0AE5A5118A5

Q28236198-1070CC17-9806-4694-B39B-1EE13E830255

Q28236198-1131EDC5-880C-48BC-A93B-B649F128F654

Q28236198-19C5A6B5-4459-4062-9FF9-1521537FA61E

Q28236198-2D94C20D-C48E-45E6-B5F9-C6216FF53C81

Q28236198-30D51EE8-6FF0-465E-93C2-980A6BE6BA15

Q28236198-391AC643-1DDC-494D-A268-5E4B90654BB8

P2888

Q28236198-6FF02314-4437-4CC0-B0FD-91B86F44D8BB

P304

Q28236198-2195DB76-D77B-4517-A424-798C848A7E65

P31

Q28236198-2F927B1B-77A9-487B-8194-7954FA45FAAC

P3181

Q28236198-5C1613BD-CEDE-4B46-87F9-B72FAE8AC8C1

P356

Q28236198-144337D3-71AE-4A63-ABDC-B3734901B584

P407

Q28236198-2686B8C4-8A8D-4B44-8BCD-4372EB922778

P433

Q28236198-861D49A5-57C7-4A11-B260-A00AF0304D45

P478

Q28236198-7A451B95-F8D1-4E1D-BDD5-4FE368DFD9CF

P577

Q28236198-16DBC775-06D5-4F03-8A81-3E47901D1774

P5875

Q28236198-47B45813-D291-4C3A-A090-0C85369A9894

P6179

Q28236198-FBFDBE8B-47F2-4214-8C80-AE994C50EF2C

P698

Q28236198-B5BB6371-6D15-4F84-B447-F8DD29B15284

P3181

P356

P1433

Neuropsychopharmacology

P1476

Neuropharmacological profile o ...... sts: WAY-181187 and WAY-208466

@en

P2093

Albert Robichaud

http://www.w3.org/2001/XMLSchema#string

Brian Platt

http://www.w3.org/2001/XMLSchema#string

Chad E Beyer

http://www.w3.org/2001/XMLSchema#string

Deborah L Smith

http://www.w3.org/2001/XMLSchema#string

Derek Cole

http://www.w3.org/2001/XMLSchema#string

Guoming Zhang

http://www.w3.org/2001/XMLSchema#string

Lee A Dawson

http://www.w3.org/2001/XMLSchema#string

Lee E Schechter

http://www.w3.org/2001/XMLSchema#string

Michael R Brandt

http://www.w3.org/2001/XMLSchema#string

Qian Lin

http://www.w3.org/2001/XMLSchema#string

P2860

In vivo effects of the 5-HT(6) antagonist SB-271046 on striatal and frontal cortex extracellular concentrations of noradrenaline, dopamine, 5-HT, glutamate and aspartate

Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction

The 5-HT(6) receptor antagonist SB-271046 selectively enhances excitatory neurotransmission in the rat frontal cortex and hippocampus

5-ht6 receptors

A novel rat serotonin (5-HT6) receptor: molecular cloning, localization and stimulation of cAMP accumulation

5-HT6 receptor antagonists reverse delay-dependent deficits in novel object discrimination by enhancing consolidation--an effect sensitive to NMDA receptor antagonism

Immuno-localization of serotonin 5-HT6 receptor-like material in the rat central nervous system

Involvement of 5-HT6 receptors in nigro-striatal function in rodents

A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression

Impairment of GABAergic transmission in depression: new insights from neuroimaging studies.

P2888

P304

1323-35

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

2129437

http://www.w3.org/2001/XMLSchema#string

P356

10.1038/SJ.NPP.1301503

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

33

http://www.w3.org/2001/XMLSchema#string

P577

2008-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6211684

http://www.w3.org/2001/XMLSchema#string

P6179

1052422555

http://www.w3.org/2001/XMLSchema#string

P698

17625499

http://www.w3.org/2001/XMLSchema#string